Navigation Links
Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
Date:6/9/2008

bipolar disorder are able to make informed decisions regarding their treatment in an acute agitated state and would prefer a treatment option that is rapid-acting and noninvasive.

Alexza believes there is a significant unmet medical need for an alternative treatment option for acute agitation that will provide a faster onset of effect, that is non-invasive and safe for medical personnel to administer, and will facilitate trust between the patient and the treating clinician.

About AZ-004 (Staccato loxapine)

AZ-004 is the combination of Alexza's proprietary Staccato system with loxapine, a drug belonging to the class of compounds known generally as atypical antipsychotics. The Staccato system technology used in AZ-004 is a hand-held, chemically-heated, single dose inhaler designed to generate and deliver excipient-free loxapine aerosol for deep lung delivery that results in IV-like pharmacokinetics. Alexza has now completed four clinical trials with AZ-004, this 344 patient Phase 3 study, a 50 subject Phase 1 study, a 129 patient Phase 2 study, and a 32 patient multiple-dose tolerability and PK study in schizophrenic patients.

The Company believes that the unique delivery of loxapine via the Staccato system will provide rapid onset of drug effect, as measured by a reduction in the signs and symptoms of acute agitation. In March 2007, Alexza announced positive initial results from a multi-center, randomized, double-blind, placebo-controlled Phase 2 clinical trial in 129 patients in an in-patient clinical setting. The 10 mg dose of AZ-004 met the primary endpoint of the clinical trial, which was a statistically significant reduction in the measure of agitation from baseline to the 2-hour post-dose time point, as compared to placebo. The 10 mg dose of AZ-004 also exhibited a rapid onset of effect, with a statistically significant improvement in the PEC scores at 20 minutes post-dose, as compared to placebo, and sustained effectiveness through
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
2. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
3. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
4. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
5. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
6. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
7. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
8. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
9. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014 ... visitors to Safety & Health Expo 2014 ... the move to London ... management attending exhibition.     ... http://photos.prnewswire.com/prnh/20140711/696892-a )      ...
(Date:7/10/2014)... NEWS, Virginia , 11. Juli ... Hersteller von Kameras für die molekulare ... (MBI/BSGI), hat heute die CE-Zulassung für ... dem CE-Zeichen kann Dilon das Produkt ... Vertriebsbereich auf den Großteil der europäischen ...
(Date:7/10/2014)... , July 10, 2014 Integrated Silicon ... in advanced memory and analog IC solutions, today announced ... Thursday, July 24, 2014, at 7:00 a.m. Pacific Time ... results for the fiscal 2014 third quarter ended June ... via telephone, dial 1-888-556-4997 before 6:50 a.m. Pacific time ...
Breaking Medicine Technology:UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 3UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 4Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2
... The Detroit Medical Center (DMC) Cardiovascular Institute (CVI) ... to successfully open a patient,s blocked artery with a ... drill" to painlessly remove the plaque buildup which causes ... – conducted Wednesday by CVI Director of Endovascular Medicine ...
... HistoRx, the leader in quantitative immunohistochemistry, advances ... recent issuance of US patents covering key features ... results.  The U.S. Patent and Trademark Office has ... for standardization of digital microscopy instruments, methods required ...
Cached Medicine Technology:DMC Cardiovascular Institute Physician is First in Michigan to Use New "Arterial Drill" Catheterization Technique to Remove a Major Blockage 2DMC Cardiovascular Institute Physician is First in Michigan to Use New "Arterial Drill" Catheterization Technique to Remove a Major Blockage 3HistoRx Earns Two Additional Patents on Standardization of Results from Digital Pathology Instruments 2HistoRx Earns Two Additional Patents on Standardization of Results from Digital Pathology Instruments 3
(Date:7/13/2014)... MillionaireCasket.com is a professional supplier of funeral products. According to ... well in the global market. Recently, the company has announced ... a special offer for all the newly released items. ... caskets are made with superb materials. As is commonly noted, ... respect to the departed saint. MillionaireCasket.com is always here to ...
(Date:7/13/2014)... 13, 2014 Intraocular Lens (IOL) Market: ... 2013 - 2019 , Intraocular lens (IOL) is inserted ... or cataracts. The lenses are inserted inside the eye, ... intraocular lens replaces the focusing power of natural lens. ... lens to deliver the light focusing function which was ...
(Date:7/13/2014)... Victorian Hotel has recently announced that ... of bikes for its "Cycle the City" program, which ... tour the area using a rental bicycle, available for ... to call Vancouver home, as it is a city ... picturesque journeys through the countryside. Vancouver hotel rooms often ...
(Date:7/13/2014)... additives are chemicals, which are added to various fuels ... on, in order to enhance their performance. Fuel additives ... by fuels and improving the combustion properties of fuels. ... scale in the long run, but, in the short ... products. , The various fuel additive types include deposit ...
(Date:7/13/2014)... The Pearland, Texas location of The Little Gym, a ... to 12 years of age that offers everything from gymnastics, ... Summer Camps, is now under new ownership. , Kevin Berry ... spending over six years at The Little Gym of Bellaire ... Berry has over ten years of experience working with children, ...
Breaking Medicine News(10 mins):Health News:Brand New Cherry Caskets Unveiled By China Casket Supplier MillionaireCasket.com 2Health News:Intraocular Lens (IOL) Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 2Health News:Intraocular Lens (IOL) Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 3Health News:Intraocular Lens (IOL) Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 4Health News:Victorian Hotel Creates Excitement by Adding "Cycle the City" Bike Rentals for Its Vancouver Hotel Rooms 2Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 2Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 3Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 4Health News:The Little Gym of Pearland, TX Now Under New Ownership and Management 2
... ... received its first batch of Spirits Bay Manuka Honey tested for activity using ... is a registered trademark of the University of Waikato, home of the Honey ... of manuka honey. Produced by a Maori-owned apiary in a remote area of ...
... ... employee wellness programs , ... GA (Vocus) April 7, 2010 -- R. Shane Jackson, president of LocumTenens.com and ... for Health Transformation,s (CHT) first member meeting of 2010, which took place on March 25 ...
... poor people have higher death rates than rich within first decade ... more likely to die within five to 10 years after heart ... 15,156 white men, 6,932 white women, 678 black men and 564 ... and 2005 and found that the poorest patients were 19 to ...
... , ... today released version 4.3 of Replay, the award-winning, next generation backup and disaster recovery ... ... 4.3 of Replay, the award-winning, next generation backup and disaster recovery software solution. ...
... a means of heterosexual interaction on university campuses, more women ... women rate hooking up above dating. Both genders however perceive ... Bradshaw from James Madison University in Virginia, US, and colleagues ... hook up or to date, as well as the perceived ...
... vaccine were at higher risk, study found, but that ... (HealthDay News) The traditional seasonal flu vaccine may ... swine flu, according to the results of four new ... researchers used an ongoing sentinel monitoring system to assess ...
Cached Medicine News:Health News:Koru Naturals Becomes the First U.S. Company to Import Molan Gold Standard Manuka Honey 2Health News:R. Shane Jackson Selected as Panelist for Center for Health Transformation Member Meeting 2Health News:R. Shane Jackson Selected as Panelist for Center for Health Transformation Member Meeting 3Health News:Poor More Likely to Die Following Heart Surgery 2Health News:De-Duplication, Compression and No Double Backups Required: AppAssure Releases the Fastest and Most Scalable Backup & Recovery Solution for Microsoft Hyper-V 2Health News:De-Duplication, Compression and No Double Backups Required: AppAssure Releases the Fastest and Most Scalable Backup & Recovery Solution for Microsoft Hyper-V 3Health News:Hooking up or dating: Who benefits? 2Health News:Did 'Regular' Flu Shot Up Risks for H1N1 Flu? 2
The Freedom Clear® LS Long Seal is a 100% latex-free, self-adhering, one piece catheter with an ultra-thin sheath for everyday wear. Its long seal provides added security....
Freedom Clear® SS Sport Sheath is a 100% latex-free, self-adhering, one piece catheter with an ultra-thin sheath designed for everyday wear. Its brief sheath minimizes roll at the base of the p...
The UltraFlex® all silicone self-adhering male external catheter is 100% latex-free and eliminates the risk of latex-related skin irritations. This breathable catheter promotes healthy skin and i...
... all-silicone Foley catheters eliminate patient exposure ... catheter designs. As an inert, toxin-free ... a safe, dependable Foley catheter. Unlike ... catheters will not leach chemicals or ...
Medicine Products: